Reversible posterior leukoencephalopathy syndrome (RPLS) is characterized by subacute onset of headache, decreased alertness, vomiting, seizures, visuoperceptual disturbances, together with bilateral white matter lesions in posterior brain regions on brain imaging. The most frequently associated conditions related to RPLS are arterial hypertension and the use of immunosuppressive or cytotoxic treatment. T2-, Fluid Attenuation Inversion Recovery (FLAIR), and Apparent Diffusion Coefficient (ADC)-weighted magnetic resonance imaging (MRI) reveal hyperintensities in parietooccipital white matter but grey matter and other regions including frontal and temporal lobes, brainstem, cerebellum, basal ganglia, or even spinal cord may also be involved. According to ADC findings, the underlying pathophysiologic mechanism is probably one of vasogenic (rather than cytotoxic) oedema. These MRI findings help in differentiating RPLS from ischaemic events and other diseases resembling RPLS. Failure of cerebral autoregulation, endothelial dysfunction, disrupted blood-brain barrier, vasospasm, and direct toxic drug effects may all play a role in the pathophysiology of RPLS. Treatment consists of discontinuation of the causal drug, treatment of high blood pressure, and antiepileptic therapy. Clinical recovery and regression of radiological abnormalities are typically seen after early treatment. However, delay in diagnosis and treatment can result in irreversible brain damage, often in association with complicating cerebral infarction or haemorrhage.
introduction
Reversible posterior leukoencephalopathy syndrome (RPLS) was first described by Hinchey et al in 1996 who reported 15 patients with a wide variety of diseases presenting with headache, decreased alertness, vomiting, seizures, and visuoperceptual disturbances [1] . Of these 15 patients, 7 had previously received immunosuppressive treatment, 1 was on interferon treatment, 3 had eclampsia, and 4 suffered from acute hypertensive encephalopathy related to renal disease. In 12 of these patients, arterial hypertension was noted.
Brain imaging showed bilateral extensive white matter abnormalities suggestive of oedema in the posterior cerebral regions. In all 15 patients, neurological abnormalities resolved after antihypertensive treatment and withdrawal or dose reduction of immunosuppressive therapy. Prior to this initial description, several patients with similar clinical findings and radiological abnormalities had been described (e.g. associated with malign hypertension, eclampsia, or cyclosporine use) [2] [3] [4] . Most RPLS patients are adults. However, RPLS can also occur in children and is the most common abnormality leading to seizures in children with leukaemia [5] .
Most of the literature concerning RPLS is based on reports of single or multiple cases rather than consecutive series of at-risk populations. To the best of our knowledge no reliable estimates of incidence of RPLS are available. Furthermore, the condition may be underdiagnosed: the clinical syndrome of RPLS is often incomplete, magnetic resonancy imaging (MRI) is not always performed, and symptoms may be reversible In principle, RPLS should be distinguished from more diffuse toxic leukoencephalopathies that lack any posterior predilection and by definition affect periventricular white matter and the centrum semiovale relatively evenly [6] (see below).
Post-mortem studies of RPLS reveal relatively aspecific changes, such as oedema, reactive astrocytosis, neuronal loss, demyelination, ischaemic infarction, and haemorrhage.
Risk factors
Drugs associated with RPLS are often -but not limited to -immunosuppressive and cytotoxic agents ( Table 1) .
The exact offending drug is sometimes difficult to identify since oncological patients undergoing chemotherapy or transplant patients on immunosuppressive medication typically receive multiple drugs that could contribute to the development of RPLS. The RPLS risk associated with specific drugs is hard to quantify since most of the literature consists of case reports rather than prevalence studies in at-risk populations. RPLS symptom onset is often related to the introduction of new drugs, dose increase, or increased blood pressure but can also occur in patients on stable doses of chronically used drugs [7] . Drug levels above the therapeutic range may play a role in the development of RPLS although in most of the reports drug levels were within the therapeutic range [8] [9] . Some drugs can indirectly lead to RPLS because they affect the pharmacodynamics of immunosuppressant agents. For instance, introduction of omeprazole in a patient chronically treated with methotrexate can lead to RPLS. Drugs that inhibit the cytochrome P450 system, such as steroids, can increase cyclosporine levels. The drug administration route influences the risk and severity of RPLS.
For instance, intrathecally administered methotrexate and cytarabine are associated with a higher risk than intravenous administration and intravenous administration of cyclosporine leads to a higher risk than oral administration [10] . These distinctions however are not absolute and long-term oral methotrexate therapy, for instance, can also give rise to RPLS [7] . The risk of developing RPLS also appears to be higher if chemotherapy is combined with cranial radiation [11] . Hypertension seems to play an important role in the pathophysiology of RPLS since blood pressure is elevated in the vast majority of reported cases. However, RPLS can occur in the absence of elevated blood-pressure readings. Electrolyte imbalance, sepsis, fever, and renal failure may predispose to RPLS through damage of the blood-brain barrier (BBB) leading to vasogenic oedema at blood pressure levels that usually would be well tolerated [12] [13] . Hypocholesterolaemia has also been described as a possible risk factors for RPLS [14] [15] [16] . Hypomagnesaemia is also a risk factor for RPLS [17] . Hypomagnesaemia can occur as a side effect of cyclosporine treatment because cyclosporine causes intracellular migration and renal wasting of magnesium [18] .
Tumor lysis syndrome, most commonly associated with Burkitt or other high-grade lymphoma and leukaemia, is another risk factor for RPLS [19] [20] . 
clinical features
The if the brainstem is involved [38] . Contrastenhancement is exceptional but may occur at the earliest stage [39] . In case of persistent offense of BBB (such as with TTP), the contrastenhancement phase may be prolonged.
Occurrence of acute cerebral haemorrhage and ischaemia may also prolong the period of contrast-enhancement [39] . Table 2 .
The distinction between ischaemia and RPLS has important therapeutic implications:
reducing blood pressure minimizes vasogenic In diffuse toxic leukoencephalopathy [6] MRI changes are by definition more evenly 
Future directions

